Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas

[1] Stiller CA(2013)Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project Eur J Cancer 49 684-695

[2] Trama A(2018)Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 29 iv268-iv269

[3] Serraino D(2017)Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial Lancet Oncol 18 812-822

[4] Casali PG(2018)High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomised clinical trial Eur J Cancer 93 28-36

[5] Abecassis N(2010)Immunity, inflammation, and cancer Cell 140 883-899

[6] Aro HT(2018)Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis Medicine (Baltimore) 97 e12176-3453

[7] Gronchi A(2019)Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study Cancer Manag Res 11 3445-249

[8] Ferrari S(2019)Serum biomarkers as prognostic factors for metastatic sarcoma Clin Oncol (R Coll Radiol) 31 242-374

[9] Quagliuolo V(2018)Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma Int J Clin Oncol 23 368-9550

[10] Pasquali S(2015)Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma Oncotarget 6 9542-1497

[1] Stiller CA(2013)Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project Eur J Cancer 49 684-695

[2] Trama A(2018)Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 29 iv268-iv269

[3] Serraino D(2017)Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial Lancet Oncol 18 812-822

[4] Casali PG(2018)High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomised clinical trial Eur J Cancer 93 28-36

[5] Abecassis N(2010)Immunity, inflammation, and cancer Cell 140 883-899

[6] Aro HT(2018)Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis Medicine (Baltimore) 97 e12176-3453

[7] Gronchi A(2019)Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study Cancer Manag Res 11 3445-249

[8] Ferrari S(2019)Serum biomarkers as prognostic factors for metastatic sarcoma Clin Oncol (R Coll Radiol) 31 242-374

[9] Quagliuolo V(2018)Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma Int J Clin Oncol 23 368-9550

[10] Pasquali S(2015)Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma Oncotarget 6 9542-1497